154 related articles for article (PubMed ID: 17209529)
1. Drug evaluation: the thioredoxin inhibitor PX-12 in the treatment of cancer.
Galmarini CM
Curr Opin Investig Drugs; 2006 Dec; 7(12):1108-15. PubMed ID: 17209529
[TBL] [Abstract][Full Text] [Related]
2. A Phase I pharmacokinetic and pharmacodynamic study of PX-12, a novel inhibitor of thioredoxin-1, in patients with advanced solid tumors.
Ramanathan RK; Kirkpatrick DL; Belani CP; Friedland D; Green SB; Chow HH; Cordova CA; Stratton SP; Sharlow ER; Baker A; Dragovich T
Clin Cancer Res; 2007 Apr; 13(7):2109-14. PubMed ID: 17404093
[TBL] [Abstract][Full Text] [Related]
3. A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy.
Ramanathan RK; Stephenson JJ; Weiss GJ; Pestano LA; Lowe A; Hiscox A; Leos RA; Martin JC; Kirkpatrick L; Richards DA
Invest New Drugs; 2012 Aug; 30(4):1591-6. PubMed ID: 21863237
[TBL] [Abstract][Full Text] [Related]
4. A phase IB trial of 24-hour intravenous PX-12, a thioredoxin-1 inhibitor, in patients with advanced gastrointestinal cancers.
Baker AF; Adab KN; Raghunand N; Chow H; Stratton SP; Squire SW; Boice M; Pestano LA; Kirkpatrick DL; Dragovich T
Invest New Drugs; 2013 Jun; 31(3):631-641. PubMed ID: 22711542
[TBL] [Abstract][Full Text] [Related]
5. A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination.
Ramanathan RK; Abbruzzese J; Dragovich T; Kirkpatrick L; Guillen JM; Baker AF; Pestano LA; Green S; Von Hoff DD
Cancer Chemother Pharmacol; 2011 Mar; 67(3):503-9. PubMed ID: 20461382
[TBL] [Abstract][Full Text] [Related]
6. Thioredoxin-1 inhibitor, 1-methylpropyl 2-imidazolyl disulfide, inhibits the growth, migration and invasion of colorectal cancer cell lines.
Wang F; Lin F; Zhang P; Ni W; Bi L; Wu J; Jiang L
Oncol Rep; 2015 Feb; 33(2):967-73. PubMed ID: 25483731
[TBL] [Abstract][Full Text] [Related]
7. The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma.
Baker AF; Dragovich T; Tate WR; Ramanathan RK; Roe D; Hsu CH; Kirkpatrick DL; Powis G
J Lab Clin Med; 2006 Feb; 147(2):83-90. PubMed ID: 16459166
[TBL] [Abstract][Full Text] [Related]
8. The Thioredoxin-1 Inhibitor, PX-12, Suppresses Local Osteosarcoma Progression.
Kinoshita H; Shimozato O; Ishii T; Kamoda H; Hagiwara Y; Ohtori S; Yonemoto T
Anticancer Res; 2021 Dec; 41(12):6013-6021. PubMed ID: 34848455
[TBL] [Abstract][Full Text] [Related]
9. Parallel syntheses of disulfide inhibitors of the thioredoxin redox system as potential antitumor agents.
Kirkpatrick DL; Watson S; Kunkel M; Fletcher S; Ulhaq S; Powis G
Anticancer Drug Des; 1999 Oct; 14(5):421-32. PubMed ID: 10766297
[TBL] [Abstract][Full Text] [Related]
10. The thioredoxin-1 inhibitor 1-methylpropyl 2-imidazolyl disulfide (PX-12) decreases vascular permeability in tumor xenografts monitored by dynamic contrast enhanced magnetic resonance imaging.
Jordan BF; Runquist M; Raghunand N; Gillies RJ; Tate WR; Powis G; Baker AF
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):529-36. PubMed ID: 15701837
[TBL] [Abstract][Full Text] [Related]
11. Synergistic interaction between thioredoxin inhibitor 1-methylpropyl 2-imidazolyl disulfide and sorafenib in liver cancer cells.
Cao LP; Zhang C; Weng XY; Xie HY; Wu J; Zheng SS
Hepatobiliary Pancreat Dis Int; 2020 Jun; 19(3):295-298. PubMed ID: 32247719
[No Abstract] [Full Text] [Related]
12. Drug evaluation: Bay-59-8862.
Eckstein JW
IDrugs; 2004 Jun; 7(6):575-81. PubMed ID: 15197663
[TBL] [Abstract][Full Text] [Related]
13. Effects of the thioredoxin-1 inhibitor PX-12 on blood-brain barrier permeability in the early stage of focal cerebral ischemia.
Chi OZ; Barsoum S; Grayson J; Liu X; Weiss HR
Pharmacology; 2013; 92(3-4):175-81. PubMed ID: 24060905
[TBL] [Abstract][Full Text] [Related]
14. Canertinib pfizer.
Galmarini CM
IDrugs; 2004 Jan; 7(1):58-63. PubMed ID: 14730468
[TBL] [Abstract][Full Text] [Related]
15. Edotecarin.
Denny WA
IDrugs; 2004 Feb; 7(2):173-7. PubMed ID: 15057663
[TBL] [Abstract][Full Text] [Related]
16. Axitinib in the treatment of metastatic renal cell carcinoma.
Ho TH; Jonasch E
Future Oncol; 2011 Nov; 7(11):1247-53. PubMed ID: 22044199
[TBL] [Abstract][Full Text] [Related]
17. Drug evaluation: MGCD-0103, a histone deacetylase inhibitor for the treatment of cancer.
Kell J
Curr Opin Investig Drugs; 2007 Jun; 8(6):485-92. PubMed ID: 17621879
[TBL] [Abstract][Full Text] [Related]
18. Self-assembling nanoparticles for the release of bisphosphonates in the treatment of human cancers [WO2012042024].
Gou J; Zhang K; Tang X
Expert Opin Ther Pat; 2012 Nov; 22(11):1367-75. PubMed ID: 22925002
[TBL] [Abstract][Full Text] [Related]
19. Axitinib, a novel anti-angiogenic drug with promising activity in various solid tumors.
Choueiri TK
Curr Opin Investig Drugs; 2008 Jun; 9(6):658-71. PubMed ID: 18516765
[TBL] [Abstract][Full Text] [Related]
20. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation.
Welsh SJ; Williams RR; Birmingham A; Newman DJ; Kirkpatrick DL; Powis G
Mol Cancer Ther; 2003 Mar; 2(3):235-43. PubMed ID: 12657718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
